Nihon Kohden (OTCMKTS:NHNKY - Get Free Report) is projected to issue its resultson Tuesday, May 12th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $414.3960 million for the quarter.
Nihon Kohden (OTCMKTS:NHNKY - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.16 EPS for the quarter. The firm had revenue of $362.86 million for the quarter. Nihon Kohden had a net margin of 5.32% and a return on equity of 7.25%. On average, analysts expect Nihon Kohden to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Nihon Kohden Trading Up 0.6%
Shares of NHNKY stock traded up $0.06 during trading hours on Tuesday, hitting $9.19. 38,045 shares of the company's stock were exchanged, compared to its average volume of 31,117. Nihon Kohden has a 12-month low of $8.93 and a 12-month high of $14.21. The company has a market capitalization of $1.57 billion, a PE ratio of 18.02 and a beta of 0.41. The business's 50 day simple moving average is $9.76 and its 200-day simple moving average is $10.70.
Analyst Ratings Changes
NHNKY has been the topic of several recent analyst reports. Zacks Research upgraded shares of Nihon Kohden to a "hold" rating in a report on Monday, April 27th. UBS Group upgraded shares of Nihon Kohden from a "hold" rating to a "strong-buy" rating in a report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Nihon Kohden presently has an average rating of "Buy".
Read Our Latest Analysis on Nihon Kohden
Nihon Kohden Company Profile
(
Get Free Report)
Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan's earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.
The company's core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nihon Kohden, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nihon Kohden wasn't on the list.
While Nihon Kohden currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.